Pancreatic Cancer Research

ResearcherUniversity of Occupational and Environmental Health JapanNo recent work listed

Keiji Hirata

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-6461-5109; OpenAlex author ID A5071060001. Sources: OpenAlex.

Their work

Papers
16 (first author 0, last author 12)
Trials
0
Grants
0
Labs led
1
Collaborators
11
Papers, trials and grants by year

2015: 1 paper · 2016: 6 papers · 2017: 2 papers · 2018: 1 paper · 2019: 1 paper · 2020: 1 paper · 2021: 2 papers · 2022: 2 papers

Papers 16

  1. Concurrent Overexpression of Two Hyaluronidases, KIAA1199 and TMEM2, Strongly Predicts Shorter Survival After Resection in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1097/mpa.0000000000002106↗
  2. Prognostic and functional role of hyaluronan-binding protein 1 in pancreatic ductal adenocarcinoma. Last author DOI 10.3892/ol.2022.13343↗
  3. Hypoxia increases KIAA1199/CEMIP expression and enhances cell migration in pancreatic cancer. Last author DOI 10.1038/s41598-021-97752-z↗
  4. Hypoxia Increases KIAA1199/CEMIP Expression and Enhances Cell Migration in Pancreatic Cancer Last author DOI 10.21203/rs.3.rs-219524/v1↗
  5. Overexpression of transmembrane protein 2 (TMEM2), a novel hyaluronidase, predicts poor prognosis in pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.pan.2020.08.026↗
  6. Hyaluronan activated-metabolism phenotype (HAMP) in pancreatic ductal adenocarcinoma. Co-author DOI 10.18632/oncotarget.27172↗
  7. 4-Methylumbelliferone inhibits enhanced hyaluronan synthesis and cell migration in pancreatic cancer cells in response to tumor-stromal interactions. Last author DOI 10.3892/ol.2018.8147↗
  8. KIAA1199/CEMIP/HYBID overexpression predicts poor prognosis in pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.pan.2016.12.007↗
  9. KIAA1199 is induced by inflammation and enhances malignant phenotype in pancreatic cancer. Last author DOI 10.18632/oncotarget.15052↗
  10. A novel epigenetic mechanism regulating hyaluronan production in pancreatic cancer cells. Last author DOI 10.1007/s10585-015-9771-9↗
  11. Targeting hyaluronan for the treatment of pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.apsb.2016.01.002↗
  12. Increased Expression of HYAL1 in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1097/mpa.0000000000000670↗
  13. Role of hyaluronan in pancreatic cancer biology and therapy: Once again in the spotlight. Co-author DOI 10.1111/cas.12913↗
  14. Hyaluromycin, a Novel Hyaluronidase Inhibitor, Attenuates Pancreatic Cancer Cell Migration and Proliferation. Co-author DOI 10.1155/2016/9063087↗
  15. Hyaluronan stimulates pancreatic cancer cell motility. Co-author DOI 10.18632/oncotarget.6617↗
  16. Receptor for Hyaluronic Acid-Mediated Motility is Associated with Poor Survival in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.7150/jca.12990↗

Closest collaborators

The 11 strongest of 11 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Shiro Kohi · 16 shared papers, 2015–2022 · strength 1.62
  2. Norihiro Sato · 16 shared papers, 2015–2022 · strength 1.62
  3. Atsuhiro Koga · 13 shared papers, 2015–2022 · strength 1.25
  4. Yuzan Kudo · 6 shared papers, 2019–2022 · strength 0.83
  5. Yasuhiro Adachi · 5 shared papers, 2020–2022 · strength 0.71
  6. Takuya Oba · 4 shared papers, 2021–2022 · strength 0.60
  7. Xiaobo Cheng · 7 shared papers, 2015–2018 · strength 0.55
  8. Toshiyuki Nakayama · 3 shared papers, 2020–2022 · strength 0.43
  9. Michael Goggins · 2 shared papers, 2016–2019 · strength 0.21
  10. Masanori Hisaoka · 1 shared paper, 2017 · strength 0.08
  11. Yasuhiro Igarashi · 1 shared paper, 2016 · strength 0.07

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.